What question did this study set out to answer?

March 1, 2026

Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.

Key Points

To examine how different patterns of BCG failure affect the efficacy of intravesical gemcitabine/docetaxel treatment in high-risk non-muscle-invasive bladder cancer.
Analyzed outcomes of intravesical gemcitabine/docetaxel based on BCG failure types
Categorized BCG failures into late relapse and refractory disease
Evaluated treatment efficacy across these categories
Late BCG relapsers showed the best treatment outcomes
Refractory BCG disease had the lowest control rates
Implications for selecting candidates for post-BCG treatment were highlighted

Abstract

Gemcitabine/docetaxel demonstrated meaningful activity across all BCG failure types, with late BCG relapsing patients achieving the most favourable outcomes and refractory disease showing the poorest control. These findings underscore the clinical relevance of distinguishing BCG failure subtypes when selecting candidates for post-BCG intravesical gemcitabine/docetaxel and designing future prospective trials.

Bookmark

Cite This Study

Scilipoti et al. (Wed,) studied this question.

synapsesocial.com/papers/69a3d873ec16d51705d2f552 https://doi.org/https://doi.org/10.1111/bju.70182

Bookmark